Novel immunotherapies in multiple myeloma – chances and challenges
Abstract: In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Haematologica. - 106, 10 (2021) , 2555-2565, ISSN: 1592-8721
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2021
- DOI
-
10.3324/haematol.2020.266858
- URN
-
urn:nbn:de:bsz:25-freidok-2195050
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:52 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
Time of origin
- 2021
Other Objects (12)
Multiple myeloma
Necessity, challenges and opportunities of novel immunotherapies for the treatment of multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Characterization of Novel Mutations in Receptor-Tyrosine Kinases in Multiple Myeloma
Protein tyrosine phosphatases in multiple myeloma
Signaling pathway profiling in multiple myeloma
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Establishment of new multiple myeloma mouse models
Multiple myeloma
Necessity, challenges and opportunities of novel immunotherapies for the treatment of multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Characterization of Novel Mutations in Receptor-Tyrosine Kinases in Multiple Myeloma
Protein tyrosine phosphatases in multiple myeloma
Signaling pathway profiling in multiple myeloma
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Establishment of new multiple myeloma mouse models
Multiple myeloma
Necessity, challenges and opportunities of novel immunotherapies for the treatment of multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Characterization of Novel Mutations in Receptor-Tyrosine Kinases in Multiple Myeloma
Protein tyrosine phosphatases in multiple myeloma
Signaling pathway profiling in multiple myeloma
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications